Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.

BMC bioinformatics - 18 Apr 2023

Li He, Yang Lei, Wang Yuanyuan, Wang Lingchan, Chen Gang, Zhang Li, Wang Dongchang

Abstract excerpt

BACKGROUND: The TP53 tumor suppressor gene is one of the most mutated genes in lung adenocarcinoma (LUAD) and plays a vital role in regulating the occurrence and progression of cancer. We aimed to elucidate the association between TP53 mutations, response to immunotherapies and the prognosis of LUAD. METHODS: Genomic, transcriptomic, and clinical data of LUAD were downloaded from The Cancer Genome Atlas (TCGA)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ferroptosis and cancer prognosis

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 37072703
DOI: 10.1186/s12859-023-05268-2
PMCID: PMC10114340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrative analysis of TP53 mutations in lung adenocarcinoma for immunotherapies and prognosis.PMID 37072703Read ↗

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.Semantic proximity Read ↗

Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma.Semantic proximity Read ↗

Clinical and Prognostic Implications of an Immune-Related Risk Model Based on TP53 Status in Lung AdenocarcinomaSemantic proximity Read ↗

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.Semantic proximity Read ↗

A special prognostic indicator: tumor mutation burden combined with immune infiltrates in lung adenocarcinoma with TP53 mutationSemantic proximity Read ↗

A TP53 Related Immune Prognostic Model for the Prediction of Clinical Outcomes and Therapeutic Responses in Lung Adenocarcinoma.Semantic proximity Read ↗

Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.Semantic proximity Read ↗

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.Semantic proximity Read ↗

Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.Semantic proximity Read ↗

Differences in Genetics and Microenvironment of Lung Adenocarcinoma Patients with or without TP53 MutationSemantic proximity Read ↗

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Semantic proximity Read ↗

TP53 CpG Site Mutations Predict the Survival of First-Line Chemoimmunotherapy in Advanced Lung Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.